Li B, Wang Q X, Ma X
Department of Gastroenterology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Institute of Digestive Disease, Shanghai 200001, China.
Zhonghua Gan Zang Bing Za Zhi. 2017 Feb 20;25(2):100-104. doi: 10.3760/cma.j.issn.1007-3418.2017.02.004.
Autoimmune liver diseases are a group of abnormal autoimmune-mediated inflammatory hepatobiliary injuries, mainly including autoimmune hepatitis(AIH), primary biliary cholangitis(PBC), and primary sclerosing cholangitis (PSC). The diagnosis and treatment of autoimmune liver diseases, an important type of non-viral liver disease, have become a prominent issue in hepatology. In 2016, many new advances have been achieved in the clinical and basic research on autoimmune liver diseases, including the phase 3 clinical trial of obeticholic acid, the proposal of UK-PBC risk score, and the research on gut microbiota associated with PSC. This article reviews the research advances in the diagnosis and treatment of autoimmune liver diseases in 2016.
自身免疫性肝病是一组由异常自身免疫介导的炎症性肝胆损伤疾病,主要包括自身免疫性肝炎(AIH)、原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)。自身免疫性肝病作为非病毒性肝病的一种重要类型,其诊断和治疗已成为肝病学领域的一个突出问题。2016年,自身免疫性肝病的临床和基础研究取得了许多新进展,包括奥贝胆酸的3期临床试验、英国PBC风险评分的提出以及与PSC相关的肠道微生物群研究。本文综述了2016年自身免疫性肝病诊断和治疗方面的研究进展。